MedPath

Levosimendan

Generic Name
Levosimendan
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C14H12N6O
CAS Number
141505-33-1
Unique Ingredient Identifier
C6T4514L4E
Background

Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

Indication

For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.

Associated Conditions
Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure
Associated Therapies
Positive cardiac inotropic effect, Intravenous inotropic therapy
Clinical Trials
Related News

Effect of Levosimendan on miRNAs Regulation in the Failing Hearts

Phase 4
Conditions
Heart Failure
Interventions
Drug: levosimendan
First Posted Date
2021-07-06
Last Posted Date
2021-07-16
Lead Sponsor
Tongji Hospital
Target Recruit Count
136
Registration Number
NCT04950569
Locations
🇨🇳

Tongji Hospital, Wuhan, Hubei, China

Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock

Completed
Conditions
Cardiorenal Syndrome
Acute Kidney Failure
Cardiogenic Shock
Interventions
Drug: Levosimendan
First Posted Date
2021-06-08
Last Posted Date
2021-06-08
Lead Sponsor
University of Zurich
Target Recruit Count
43
Registration Number
NCT04917497

LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients

Phase 3
Recruiting
Conditions
Cardiogenic Shock
Extracorporeal Membrane Oxygenation Complication
Interventions
Drug: Placebo of Levosimendan
Drug: Levosimendan
First Posted Date
2021-01-28
Last Posted Date
2023-11-27
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
206
Registration Number
NCT04728932
Locations
🇫🇷

Hôpital du Haut-Lévêque, Pessac, Bordeaux, France

🇫🇷

Hôpital Pitié Salpêtrière, Paris, France

🇫🇷

Hôpital Européen Georges Pompidou, Paris, France

Levosimendan In Ambulatory Heart Failure Patients

Phase 4
Not yet recruiting
Conditions
Heart Failure New York Heart Association Class III
Heart Failure New York Heart Association Class IV
Heart Failure With Reduced Ejection Fraction
Heart Failure, Systolic
Interventions
Other: Placebo
Drug: Levosimendan
First Posted Date
2021-01-12
Last Posted Date
2021-01-12
Lead Sponsor
Medical University of Bialystok
Target Recruit Count
350
Registration Number
NCT04705337
Locations
🇵🇱

University Hospital of Lord's Transfiguration, Poznań, Poland

🇵🇱

Cardinal Stefan Wyszyński Institute of Cardiology, Warszawa, Poland

🇵🇱

Medical University Hospital No.2, Bydgoszcz, Poland

and more 11 locations

The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement

Phase 4
Conditions
Heart Failure
Effect of Drug
Cardiac Event
Inotropic Agents
Safety Issues
Transcatheter Aortic Valve Replacement
Aortic Valve Stenosis
Interventions
Other: Placebo
Drug: Levosimendan
First Posted Date
2020-10-05
Last Posted Date
2020-10-05
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
124
Registration Number
NCT04573049
Locations
🇨🇳

Jianhui Wang, Beijing, Beijing, China

Levosimendan Versus Combination With Magnesium Sulphate on Spine Protection by NIRS in Infants Undergoing Coarctectomy

Phase 4
Completed
Conditions
Aortic Coarctation
Interventions
Drug: Levosimendan
Drug: Saline Solution
Drug: Magnesium Sulfate
First Posted Date
2020-04-01
Last Posted Date
2023-10-16
Lead Sponsor
Dalia Saad Abd-El Kader
Target Recruit Count
40
Registration Number
NCT04330755
Locations
🇪🇬

Sara ABD El-Salam, Cairo, Egypt

Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients

Phase 3
Active, not recruiting
Conditions
Cardiovascular Risk Factor
Interventions
Drug: Placebo
Drug: Levosimendan
First Posted Date
2020-04-01
Last Posted Date
2024-03-26
Lead Sponsor
Medical University of Vienna
Target Recruit Count
230
Registration Number
NCT04329624
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Spanish Randomized Clinical Trial to Compare Levosimendan Versus Placebo in Postoperative Cardiac Surgery (SPARTANS)

Phase 2
Conditions
Cardiac Output, Low
Interventions
Drug: Placebos
Drug: Levosimendan
First Posted Date
2019-11-27
Last Posted Date
2020-07-24
Lead Sponsor
María de los Ángeles Tena Pajuelo
Target Recruit Count
300
Registration Number
NCT04179604
Locations
🇪🇸

Valladolid universitary Hospital, Valladolid, Spain

🇪🇸

GERMANS TRIAS I PUJOL DE BADALONA university Hospital, Badalona, Barcelona, Spain

🇪🇸

12 de Octubre University Hospital, Madrid, Spain

and more 6 locations

Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS

Phase 3
Terminated
Conditions
Acute Decompensated Heart Failure
Interventions
Drug: Levosimendan
Drug: Cernevit
First Posted Date
2019-11-12
Last Posted Date
2024-10-01
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
82
Registration Number
NCT04158674
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis

Conditions
Sepsis
Septic Shock
Cardiogenic Shock
First Posted Date
2019-10-28
Last Posted Date
2019-10-28
Lead Sponsor
Azienda USL Toscana Centro
Target Recruit Count
35
Registration Number
NCT04141410
Locations
🇮🇹

Ospedale Santo Stefano, Prato, FI, Italy

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy